The AHA today urged the Centers for Medicare & Medicaid Services to consider alternative payment solutions to promote beneficiary access to chimeric antigen receptor T-cell (CAR T) therapy and other new technologies that “offer extraordinary potential to save lives, but are also associated with extraordinary costs.” In a letter to CMS, AHA recommended immediate and longer-term actions to “promote beneficiary access to these therapies, set appropriate precedents for how they are handled in rating setting and preserve opportunities for additional payment options in the future.” On Friday, CMS proposed that Medicare cover CAR T therapies approved by the Food and Drug Administration when they are prescribed by the treating oncologist and performed in a hospital meeting certain criteria.

Related News Articles

Headline
Fairview Health Services, a Minneapolis-based nonprofit health system of 10 hospitals and medical centers serving the greater Twin Cities metro area and north-…
Headline
The Rural Hospital Excellence in Innovation Award honors rural hospitals that are leading the way in innovative, sustainable and community-centered care. If…
Headline
AHA’s Circle of Life Award celebrates innovation in palliative and end-of-life care and seeks to provide best practices and models for the field. Programs and…
Headline
The AHA July 8 wrote in opposition to the “Patient Access to Higher Quality Health Care Act” (H.R. 4002), which would repeal current law banning the creation…
Headline
The AHA encourages hospitals and health systems that are committed to leadership and innovation in improving quality and advancing health to apply for its 2026…
Headline
The AHA July 3 released the Health Care Plan Accountability Update for the second quarter of 2025. The update covers the latest developments in Medicare…